Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This open-label, single arm phase 1/1b trial aims to determine the safety and tolerability of
anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells (CD19x22 CAR T) in
adolescents and adults with relapsed/refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).
Phase 1 will determine the maximum tolerated dose of CD19x22 CAR T cells using a standard 3+3
trial design. Phase 1b is an expansion phase designed to evaluate the preliminary efficacy of
CD19x22 CAR T in CAR-treated and CAR-naïve patients.